Using two positron emission tomography (PET) probes, one common one and one they developed themselves, researchers in the US found they can get a much clearer picture of what happens at the cellular level during an immune response…
Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
31
May |
Picture Of Immune Response Clearer With Combined PET Scanning ProbesCategory: MRI / PET / Ultrasound | Leave a Comment |
Using two positron emission tomography (PET) probes, one common one and one they developed themselves, researchers in the US found they can get a much clearer picture of what happens at the cellular level during an immune response…
|
30
May |
Mayo Clinic Discharges 1st SynCardia Total Artificial Heart Patient In U.S. HistoryCategory: Heart Disease | Leave a Comment |
On May 3, Mayo Clinic Arizona became the first hospital in U.S. history to discharge a patient implanted with the SynCardia temporary Total Artificial Heart to wait at home for a matching donor heart. Mayo Clinic is participating in an FDA Investigational Device Exemption (IDE) clinical study of the Freedom™ driver, the first ever U.S…
|
30
May |
Robotic Assisted Vasectomy Reversal Offers Greater Chance Of FatherhoodCategory: Fertility | Leave a Comment |
In 1989 a 29-year-old Michael Schrader had it all: steady job, a wife, and two wonderful children - daughter Courtney and son Cameron. He couldn’t envision wanting more - that is, more children. Taking steps to keep his nuclear family intact, he underwent vasectomy - a procedure so routine he was back on the golf course the next afternoon…
|
29
May |
OrthoDynamix LLC Receives FDA 510(k) Clearance For ArthroSteer(R) 3.5mm AblatorCategory: Bones / Orthopedics | Leave a Comment |
OrthoDynamix announced that it has received FDA clearance for its new device, ArthroSteer 3.5mm Ablator, a mono polar electrosurgical device, for general surgical use, including the orthopedic and arthroscopic applications for resection, ablation, excision of soft tissue, hemostasis of blood vessels, and coagulating soft tissue in, but not limited to the knee, shoulder, and primarily the hip…
|
29
May |
Novo Nordisk Receives FDA Approval For Norditropin® FlexPro® For Growth Hormone TreatmentCategory: Endocrinology | Leave a Comment |
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Norditropin® FlexPro® (somatropin [rDNA origin] injection), a pre-filled injection pen to be used by children and adults with growth hormone disorders. It will be available in the second quarter…
|
29
May |
KENSEY NASH Receives FDA 510(k) Clearance For ECM Product, Meso BioMatrix Surgical MeshCategory: Medical Devices / Diagnostics | Leave a Comment |
Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative resorbable biomaterial technology for a wide range of medical procedures, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its second extracellular matrix (ECM) product, the Meso BioMatrix™ product…
|
29
May |
Redsense Medical Receives FDA Clearance For The Redsense Safety Device For Home/Self Use During Home HemodialysisCategory: Urology / Nephrology | Leave a Comment |
The Redsense safety device is now cleared by FDA for Home/Self use and is consequently available to all patients with home hemodialysis in the US. Redsense safety device is designed to detect venous needle dislodgement during hemodialysis and its use has already improved in-clinic patient safety. Optimizing safety conditions for home hemodialysis users is a core ambition for Redsense Medical…
|
29
May |
Gore Receives FDA Approval For 45 Mm GORE(R) TAG(R) Thoracic EndoprosthesisCategory: Vascular | Leave a Comment |
W. L. Gore & Associates (Gore) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market a 45 mm diameter version of the GORE® TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta…
Scientists from four U.S. universities have created a way to use Rice University’s light-activated nanoshells as building blocks for 2-D and 3-D structures that could find use in chemical sensors, nanolasers and bizarre light-absorbing metamaterials…
|
29
May |
St. Jude Medical Announces European Approval For Industry-First Neurostimulation Lead Delivery System For The Management Of Chronic PainCategory: Pain / Anesthetics | Leave a Comment |
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced European CE Mark approval of its new Epiducer(TM) lead delivery system for neurostimulation therapy…